Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lonicera japonica

Drug Profile

Lonicera japonica

Alternative Names: Flos Lonicerae Japonicae - GC Pharma; GC-6101A; Japanese honeysuckle - GC Pharma; Lonicera japonica THUNB - GC Pharma; Lonicerae flos - GC Pharma

Latest Information Update: 07 Feb 2018

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Green Cross
  • Developer GC Biopharma
  • Class Kampo medicine; Traditional Chinese medicine
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Gastritis

Most Recent Events

  • 29 Jul 2016 Lonicera japonica is still in phase II trials for Gastritis in South Korea (PO) (NCT02353039)
  • 01 Sep 2014 Phase-II clinical trials in Gastritis in South Korea (PO)
  • 23 Aug 2013 Preclinical trials in Gastritis in South Korea (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top